Thermo Acquisition Gets Thumbs Up From Life Tech Stockholders

NewsGuard 100/100 Score

Life Technologies' stockholders voted to adopt the merger agreement announced back in April providing for the acquisition of Life Tech by Thermo Fisher Scientific. More than 98% of votes cast at the Special Meeting of Stockholders were in favor of the transaction, reportedly representing more than 72% of all outstanding shares.

According to the April agreement made by Life Tech's board of directors, Thermo Fisher will acquire Life Technologies for $76.00 per share in cash, subject to potential increase in certain circumstances if the merger does not close by January 14, 2014. The transaction is expected to close early in 2014, and Thermo Fisher and Life Tech said at the time that they expect to cut $85 million in costs during the first full year of the deal.

"Today's approval represents a significant milestone and brings us one step closer to joining Thermo Fisher," said Gregory T. Lucier, Life Tech chairman and CEO, in a statement. "I want to thank all of our stockholders for their support, which is a testament to the tremendous advantages and opportunities that this transaction provides to stakeholders of both companies. We look forward to joining together with Thermo Fisher in order to accelerate innovation for our customers and achieve greater success in a highly competitive global industry."


Genetic Engineering & Biotechnology News (GEN)Genetic Engineering & Biotechnology News (GEN)This article was reprinted from Genetic Engineering & Biotechnology News (GEN) with permission from Mary Ann Liebert, Inc., publishers. Genetic Engineering & Biotechnology News (GEN) has retained its position as the number one biotech publisher around the globe since its launch in 1981. GEN publishes a print edition 21 times a year and has additional exclusive editorial content online, like news and analysis as well as blogs, podcasts, webinars, polls, videos, and application notes. GEN's unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study uncovers causal genetic variant strongly associated with childhood obesity